DefiniGEN provides human liver cells for preclinical drug development and disease modelling applications using human Induced Pluripotent Stem Cell hIPSC technology.
|Telephone:||+44 (0)1223 497 113|
|Address:||Maia Building, Babraham Research Campus, Babraham|
|Membership type:||Corporate 6-20 (£250+VAT pa)|
Definigen provides human cells to the drug discovery sector for use in lead optimization and toxicity programmes. The Company’s proprietary production platform OptiDIFF robustly generates human cell types including liver hepatocytes using hIPSC human Induced Pluripotent Stem Cell technology.
Definigen has utilised the OptiDIFF platform to produce validated libraries of disease modelled human liver cells for a range of Inherited Metabolic Diseases (IMDs). The phenotype and pathology of the diseases has been confirmed in the cells and the resulting products are available for utilisation in drug discovery lead optimization studies.
DefiniGEN, the world leader in human iPSC differentiation and disease modelling, announces the appointment of Professor Sir John Savill as a Non-Executive Director of the Board.
12 September 2018Read in full
DefiniGEN, a leading provider of stem cell products and services, today announced that it has strengthened its IP portfolio with a licence for cutting-edge cholangiocyte liver technology from Cambridge Enterprise, the commercialisation arm of the University of Cambridge.
27 April 2017Read in full
DefiniGEN, a leading provider of stem cell life science products, has announced that it has raised £1.5m ($2.29m) in follow-on funding. The investment will be used to fund the commercial launch of new pancreatic and lung stem cell products for drug discovery and regenerative medicine.
23 May 2016Read in full
DefiniGEN Ltd, a leading provider of stem cell life science products and services, today announced that it has strengthened its IP portfolio with a licence for cutting edge lung stem cell technology from the University of Cambridge. The technology will be used by DefiniGEN to develop new, optimised cell products and services for drug discovery and the study of lung diseases, including cystic fibrosis.
11 August 2015Read in full
EFPIA pharmaceutical companies, SMEs, and academia join together in an IMI supported public-private partnership project to establish the leading facility for the storage and distribution of induced pluripotent stem (iPS) cells in Europe.
27 August 2014Read in full
DefiniGEN Ltd, a leading provider of stem cell life science products and services, today announced the final closing of its Series A funding round. The latest £1 million ($1.6 million) placement for ordinary shares brings to a close a cumulative total for the round of £2.28 million ($3.83 million), which will support the international expansion of the business and the commercial launch of new products.
2 June 2014Read in full